GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » Ending Cash Position

Pure Biologics (WAR:PUR) Ending Cash Position : zł1.28 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Pure Biologics Ending Cash Position?

Pure Biologics's Ending Cash Position for the quarter that ended in Sep. 2024 was zł1.28 Mil.

Pure Biologics's quarterly Ending Cash Position declined from Mar. 2024 (zł5.29 Mil) to Jun. 2024 (zł0.19 Mil) but then increased from Jun. 2024 (zł0.19 Mil) to Sep. 2024 (zł1.28 Mil).

Pure Biologics's annual Ending Cash Position declined from Dec. 2021 (zł6.18 Mil) to Dec. 2022 (zł2.26 Mil) but then increased from Dec. 2022 (zł2.26 Mil) to Dec. 2023 (zł3.61 Mil).

Pure Biologics Ending Cash Position Historical Data

The historical data trend for Pure Biologics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pure Biologics Ending Cash Position Chart

Pure Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 13.92 8.96 6.18 2.26 3.61

Pure Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.63 3.61 5.29 0.19 1.28

Pure Biologics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pure Biologics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.259+1.347
=3.61

Pure Biologics's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.192+1.089
=1.28

Pure Biologics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pure Biologics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Pure Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » Ending Cash Position
Comparable Companies
WAR:RDG WAR:GX1 WAR:NNG WAR:SCS WAR:PHR WAR:PFM WAR:URT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY
Traded in Other Exchanges
N/A
Address
ul. Dunska 11, Wroclaw, POL, 54-427
Website
http://www.purebiologics.pl
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Pure Biologics Headlines

No Headlines